Request Demo

Last update 08 May 2025

Insulin Glargine/Lixisenatide

Last update 08 May 2025

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Hormone

Synonyms

AVE0010/Lantus, Insulin glargine/Lixisenatide, Lantus/Lyxumia

+ [13]

Target

GLP-1R x INSR

Action

agonists

Mechanism

GLP-1R agonists(Glucagon-like peptide 1 receptor agonists), INSR agonists(Insulin receptor agonists)

Therapeutic Areas

Endocrinology and Metabolic Disease

Active Indication

Diabetes Mellitus, Type 2

Inactive Indication

Diabetes Mellitus, Type 1

Originator Organization

Sanofi

Active Organization

SanofiSanofi KK

Sanofi Winthrop Industrie SA

+ [2]

Inactive Organization

Sanofi (China) Investment Co. Ltd.Sanofi-Aventis Recherche et Développement SA

Sanofi SA

+ [1]

License Organization

Zealand Pharma A/S

Royalty Pharma Plc

Drug Highest PhaseApproved

First Approval Date

Switzerland (16 May 2002),

Diabetes Mellitus, Type 2

RegulationPriority Review (United States)

Structure/Sequence

Sequence Code 4851β

Sequence Code 31960α

Clinical Trials associated with Insulin Glargine/Lixisenatide

NCT06716424

/ RecruitingPhase 4

Multicentre Phase IV Single Arm Clinical Trial to Evaluate the Safety and Efficacy of a Fixed Ratio Combination of Insulin Glargine and Lixisenatide in Adult Patients With Type 2 Diabetes Who Are Sub Optimally Controlled on Oral Anti-hyperglycemic Drugs and/or Basal Insulin/GLP-1 RA

This is an intervention, phase IV, single-arm study to assess the safety and efficacy of iGlarLixi in adult patients with Type 2 diabetes.

Start Date06 Jan 2025

Sponsor / Collaborator

Sanofi

NCT06671587

/ RecruitingPhase 4

A 20-week, Multicenter, Prospective, Parallel-group Treatment, Open-label, 2-Arm, Phase 4, Randomized Study to Evaluate the Efficacy of iGlarLixi Versus Gla-100 on Glycemic Time in Range (TIR) From Continuous Glucose Monitoring (CGM) in Chinese Insulin Naïve Patients With Type 2 Diabetes (T2D) Inadequately Controlled With Oral Antidiabetics

This study is an open-label, 1:1 randomized, active-controlled, 2-arm, 20-week treatment duration, parallel-group, multicenter, phase IV study to evaluate the effect of iGlarLixi versus Gla-100 on glycemic control measured as TIR from CGM device in Chinese insulin naïve patients with T2D inadequately controlled with OADs. At the end of the screening period, eligible participants will be randomized to one of two treatment groups (iGlarLixi or Gla-100 group). The randomization (1:1) will be stratified by values of HbA1c at screening (<8.0%, ≥8.0%), and background treatment (metformin only, metformin+SGLT-2i).
Study details include:
* The study duration per participant will be approximately up to 24 weeks.
* The treatment duration will be up to 20 weeks.
* The number of visits will be 14 visits including 9 times of on-site visits and 5 times of phone call visits in total during screening and treatment periods. On-site every 1 week will be from screening till randomization (Week 0), then on site or phone call visit every 2 weeks till Week 12, then every 3 weeks till Week 18, and the End of Treatment visit will be conducted at Week 20. There will be a safety follow-up by a phone call visit (End of Study) in 3 days (-1/+3 days) after the last dose of the treatment.
* Health measurement/Observation: change in TIR as the primary endpoint
* Intervention name: iGlarLixi and Gla-100
* Participant gender: male and female
* Participant age range: adults at least 18 years of age
* Condition/disease: type 2 diabetes
* Study hypothesis: compared to Gla-100, iGlarLixi will demonstrate a superiority therapeutic effect on glycemic control assessed by change in TIR measured with CGM from baseline to Week 20 in the study participants.

Start Date10 Dec 2024

Sponsor / Collaborator

Sanofi

CTRI/2024/10/075222

/ Not yet recruitingPhase 4

A Multicentre Phase IV single arm clinical trial to evaluate the safety and efficacy of a fixed ratio combination of Insulin Glargine and Lixisenatide in adult patients with Type 2 diabetes who are sub optimally controlled on oral anti-hyperglycemic drugs and/or basal Insulin/GLP-1 RA - iGlarLixi Phase 4 study in India

Start Date28 Oct 2024

Sponsor / Collaborator

Sanofi Healthcare India Pvt Ltd.

100 Clinical Results associated with Insulin Glargine/Lixisenatide

100 Translational Medicine associated with Insulin Glargine/Lixisenatide

100 Patents (Medical) associated with Insulin Glargine/Lixisenatide

153

Literatures (Medical) associated with Insulin Glargine/Lixisenatide

01 May 2025·Diabetes, Obesity and Metabolism

Treatment satisfaction and time in range after 16 weeks of treatment with iGlarLixi in insulin‐naive adults with suboptimally controlled type 2 diabetes

Article

Author: Rodrigues, Amélie ; Meneghini, Luigi ; Dex, Terry ; Polonsky, William H. ; Shah, Viral N.

AbstractAimsIn Soli‐CGM, treatment with iGlarLixi (insulin glargine 100 U/mL and lixisenatide 33 μg/mL) in insulin‐naive adults with suboptimally controlled type 2 diabetes (T2D; haemoglobin A1c 9%–13% on ≥2 oral antihyperglycaemic agents (OADs) ± glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) therapy) increased time in range (TIR; primary endpoint) from 26.4% at baseline to 52.7% at Week 16. This exploratory analysis examined the impact of treatment with iGlarLixi on patient‐reported treatment satisfaction.Materials and MethodsSoli‐CGM was a single‐arm, 16‐week, multicentre, interventional, open‐label, phase 4 study using blinded continuous glucose monitoring (CGM; FreeStyle Libre Pro) to assess glycaemic metrics (N = 124). CGM data were collected for a 2‐week period before initiation of iGlarLixi, and after treatment with iGlarLixi (Weeks 14–16). Treatment satisfaction was assessed using the Diabetes Medication Treatment Satisfaction Tool (DM‐SAT, which comprises four domains: well‐being, medical control, lifestyle and convenience), at baseline and end‐of‐treatment. Association of TIR and overall satisfaction (sum of all items) was also assessed.ResultsOverall, 118 (95.9%) and 107 (87.0%) participants completed the DM‐SAT at baseline and Week 16, respectively. Mean overall score increased by 0.18, from 0.59 (baseline) to 0.78 (Week 16). A trend in improvement in score was observed in all domains. Improvement in TIR had a positive, but weak, trend of association with improvement in overall treatment satisfaction (mean r = 0.14).ConclusionsIn people with T2D suboptimally controlled on ≥2 OADs ± GLP‐1 RA, 16 weeks' treatment with iGlarLixi resulted in a trend of improvement in treatment satisfaction.

01 May 2025·Value in Health Regional Issues

Cost-Effectiveness Analysis of Pharmacological Treatment With Insulin and Insulin Analogs for Type 1 and Type 2 Diabetes Mellitus in Colombia

Article

Author: Plazas, Merideidy ; Morales, Christian Camilo Anzola ; Arango, Luz Karime Osorio ; Escobar, Ivan Darío ; Ramirez, Luis Esteban Orozco ; Ibáñez, Diego Fernando Ávila

OBJECTIVESThis study aimed to estimate the cost-effectiveness relationship of insulins and insulin analogs in diabetes mellitus type 1 (DM1) and 2 (DM2), from the perspective of the Colombian health system.METHODSA short-term decision tree model (SM) was built, the outcome of which was severe/nocturnal hypoglycemia, and a long-term Markov model for quality-adjusted life-years. The probabilities were calculated through a literature review of effectiveness and safety. The costs are estimated from official databases. Deterministic and probabilistic sensitivity analyses were performed.RESULTSFor DM1, in prandial insulins, and for both models, the cost-effective interventions (CEIs) are aspartate and lispro. In basal insulins, the CEIs are NPH and glargine U-100 in both models. In the comparison of detemir and NPH, detemir generates lower nocturnal hypoglycemia and higher quality-adjusted life-years; however, in the long-term Markov model, the incremental cost-effectiveness ratio exceeds the threshold. For DM2, in the prandial insulin, and for both models, aspartate is a CEI and the glargine U-300 is also a CEI in the SM. In basal insulin, the CEIs are glargine U-100 and detemir (for nocturnal hypoglycemia) in both models and glargine U-300 is also a CEI in the SM. Finally, in the group of combinations, iGlarLixi is dominant over IDegLira.CONCLUSIONSThe results favor the use of analog insulins over human insulins, the former reducing the possibility of acute events and chronic complications to a greater extent.

01 May 2025·Advances in Therapy

Safety of iGlarLixi in Japanese People with Type 2 Diabetes: A Post-marketing Database Study

Article

Author: Takahashi, Yoko ; Terauchi, Yasuo ; Morimoto, Yukiko ; Kaneto, Hideaki ; Hatanaka, Makiko

INTRODUCTIONIn this post-marketing study in Japan, the occurrence of hospital-treated hypoglycaemia and severe hyperglycaemia requiring inpatient treatment was evaluated in various cohorts of people with type 2 diabetes (T2D) newly switched to iGlarLixi, a titratable, once-daily, fixed-ratio combination of long-acting insulin glargine 100 U/mL (iGlar-100) and a glucagon-like peptide-1 receptor agonist (GLP-1 RA, lixisenatide).METHODSIn this retrospective, observational study, acute-care hospital data from adults with T2D were analysed from the Medical Data Vision database. In Cohort 1, the incidence rate of hospital-treated hypoglycaemia following newly prescribed iGlarLixi versus iGlar-100 was assessed. Cohort 2 was subdivided to evaluate the incidence rate of hospital-treated hypoglycaemia and severe hyperglycaemia requiring inpatient treatment in people switched to iGlarLixi from either a GLP-1 RA ± oral antidiabetic drugs (OADs) or OADs alone (Cohort 2A) or from a GLP-1 RA and long-acting insulin ± OADs or long-acting insulin ± OADs (Cohort 2B).RESULTSOf the 438 people in the iGlarLixi group and 9295 people in the iGlar-100 group in Cohort 1, who had a median follow-up duration of 52 and 44 days, respectively, there were zero and 0.011 (95% CI 0.006-0.018) events per person-year of hospital-treated hypoglycaemia, respectively. Cohort 2A included 201 people each in the GLP-1 RA ± OADs and OADs alone groups, with a median follow-up duration of 76 and 101 days, respectively, and Cohort 2B included 255 people in the GLP-1 RA and long-acting insulin ± OADs group and 623 people in the long-acting insulin ± OADs group, with a median follow-up duration of 73 and 62 days, respectively; no cases of hospital-treated hypoglycaemia or severe hyperglycaemia requiring inpatient treatment were observed.CONCLUSIONConsistent with clinical trials, this post-marketing database study observed that newly prescribed iGlarLixi has a low risk of serious hypoglycaemia or hyperglycaemia in Japanese people with T2D, irrespective of prior antidiabetic drug treatment.

News (Medical) associated with Insulin Glargine/Lixisenatide

14 Jun 2024

·www.pharmaceutical-technology.com

Pre-diabetes rates increase amidst a renaissance for type 2 diabetes research

There are currently six GLP-1RAs available in the UK. Image credit: Shutterstock / KK Stock. England’s National Health Service (NHS) has reported an 18% increase in the number of people with non-diabetic hyperglycaemia – also known as pre-diabetes. The latest National Diabetes Audit shows that 3,615,330 people registered with a GP have pre-diabetes and are at a greater risk of developing type 2 diabetes (T2D). Compared to 2023 figures, this is up by more than half a million patients. The NHS has rolled out a range of programmes and services to curb the proportion of this cohort that are diagnosed with T2D. However, for those who still develop diabetes, a much-changed treatment landscape now exists. Previously, metformin and other anti-hyperglycaemic medications were the only pharmaceutical options for patients with T2D. Metformin is still the first-line treatment of choice for T2D patients due to its efficacy, safety, and cost. Now, the proliferation of glucagon-like peptide-1 receptor agonists (GLP-1RAs), in particular, has transformed diabetes care. These drugs work by mimicking the GLP-1 hormone that is normally released after eating, which stimulates various glycaemic control mechanisms. See Also: FDA grants approval for Alexion’s NMOSD treatment AbbVie signs agreement to acquire Landos Biopharma for $212.5m GLP-1RA options on the NHS There are currently six GLP-1RAs available in the UK. The more popular options are Eli Lilly’s Mounjaro (tirzepatide) and Novo Nordisk ’s Ozempic (semaglutide). Novo Nordisk also markets semaglutide in the oral form as Rybelsus. Other approved treatments include Eli Lilly’s Trulicity (dulaglutide), Novo Nordisk’s Victoza (liraglutide), and Sanofi ’s Lyxumia (lixisenatide), all GLP-1RAs. The sharp rise in uptake of GLP-1RAs has outpaced supply, however, leading to shortages in the NHS earlier this year. Off-label prescribing worsened the shortages, prompting guidance from a Medicines Safety Notice in March telling clinicians to only prescribe the drugs for their licensed indication. At the same time, an increased supply of Rybelsus, and the introduction of Mounjaro in the supply chain have been highlighted by charity Diabetes UK. The shortages are likely expected to last until the end of this year, according to Douglas Twenefour, head of care at Diabetes UK. Twenefour added: “We fully support the instruction that GLP-1 medications should not be prescribed off-label under any circumstances while there is an ongoing shortage impacting people with T2D.” Global pharma scene Novo Nordisk and Eli Lilly, market leaders for GLP-1RAs, are now the two biggest pharmaceutical companies in the world. Novo Nordisk has a market cap of $436bn while Eli Lilly’s market cap is $839.5bn. Their success has meant other players in the industry have been making a push into diabetes – and more broadly weight loss – treatments. AstraZeneca received US Food and Drug Administration (FDA) approval earlier this week for its paediatric type 2 diabetes treatment Farxiga (dapagliflozin). Farxiga, marketed as Forxiga in the EU, is already approved as an adjunct to diet and exercise to improve glycaemic control in adults with T2D. The company signed a deal worth a potential $1.85bn last November to gain an exclusive licence to Eccogene’s T2D pill ECC5004, at the time in the early stages of development. Roche signalled its intent to join the GLP-1RA arena a month later with its acquisition of Carmot Therapeutics for $2.7bn, along with $400m in milestone payments. Pfizer is eying the lucrative metabolic disease market but suffered a setback after its weight loss pill, lotiglipron, caused serious side effects in a Phase IIb trial, causing the company to drop its GLP-1RA candidate . Pfizer will rest its hopes on its other candidate, danuglipron, to take on competitors.

Drug ApprovalAcquisitionPhase 2License out/in

12 Apr 2024

·www.fiercepharma.com

EU regulator finds no link between GLP-1s and suicidal thoughts

The review started after reports of suicidal thoughts and self-harm from two patients on Novo Nordisk's Ozempic and one taking Saxenda. Eight months after the European Medicines Agency (EMA) opened an investigation into a potential link between popular GLP-1 receptor agonists and suicidal thoughts or actions, the agency has determined there is no such association. The review began in July after two cases of suicidal thoughts and one instance of self-harm were reported from Icelandic users of Novo Nordisk’s blockbuster diabetes and obesity treatments. Along with Novo’s semaglutide products (marketed as Ozempic, Rybelsus and Wegovy), and its liraglutide meds (Saxenda and Victoza), the EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) looked into the company’s Xultophy. Also included in the probe were Eli Lilly’s Trulicity, AstraZeneca’s Byetta and Bydureon, and Sanofi’s Soliqua and Adlyxin (or Suliqua and Lyxumia in Europe). After asking for further data from the companies in November, the PRAC found that available evidence does not support a casual association between the drugs and suicidal or self-injurious thoughts or actions, according to a Friday release. The committee further analyzed a study based on a vast database of electronic health records, plus a similar one conducted by the EMA that only included type 2 diabetes patients. Regulators also reviewed otherwise “available studies” and post-marketing data. Even after the probe, the companies will “continue to monitor these events closely,” the European regulators noted. In parallel, the FDA has been looking into hundreds of similar reports flagged through its FDA Adverse Event Reporting System (FAERS). In January, the U.S. agency came to the same conclusion of no clear relationship, partly due to the fact that “these events can be influenced by other potential factors,” the FDA wrote. One factor may be the “known relationship between our food and our mood,” president of the Obesity Medicine Association and chief medical officer at weight-inclusive healthcare company knownwell Angela Fitch, M.D., said in an emailed statement. “When we change that relationship—whether with GLP-1s, surgery, or other methods, we need to ensure we monitor patients for mood changes regardless of treatment modality.” The FDA and EMA findings are further backed by a study from Nature Journal, which pulled data from 1.8 million diabetes and obesity patients showing those who were on Novo’s semaglutide were less likely to have suicidal thoughts than patients taking other treatments.

Clinical Study

04 Apr 2024

·firstwordpharma.com

Diabetes drug trial sparks hope GLP-1s could slow Parkinson's progression

GLP-1 agonists have flipped the script when it comes to managing diabetes and obesity, and appear to be making headway on heart health as well. But one small study has now revealed promising results for slowing the progression of motor disability in early Parkinson's disease.A growing body of evidence suggests GLP-1 agonists have neuroprotective properties that could benefit these patients. For example, some studies point to a lower risk of Parkinson's among diabetics treated with GLP-1s or DPP-4 inhibitors, which increase GLP-1 levels. Another consistent physiological finding of GLP-1 receptor activation has been reduced inflammation in the brain, a key pathological process in Parkinson's.A new paper published in the NEJM evaluated Sanofi's diabetes drug lixisenatide, marketed under the trade names Adlyxin in the US and Lyxumia in Europe, in a randomised Phase II trial of 156 patients with early Parkinson's. Subjects had already begun receiving standard therapy and were in the "on-medication" state. The primary endpoint was change from baseline on a 132-point scale measuring motor disability.Small, but significant differenceAt 12 months, patients on lixisenatide experienced less decline in their motor symptoms, with essentially no change in scores on the Movement Disorder Society–Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part III. By contrast, those in the placebo group saw their Parkinson's symptoms get worse, with an increase of 3.04 points on MDS-UPDRS, where higher scores reflect greater motor disability. The difference was small, but statistically significant.After a 2-month washout period, the mean MDS-UPDRS motor scores in the "off-medication" state were 17.7 with lixisenatide and 20.6 for placebo; that compares to baseline motor scores of approximately 15 in both groups. Secondary endpoints, which assessed scores at 6 and 12 months on different parts of the MDS-UPDRS scale including non-motor measures, did not differ substantially between the groups."It remains to be determined whether the apparent effect of the drug on motor scores persists with longer exposure and at other stages of Parkinson's disease," the study authors said.Looking beyond motor scoresIn an accompanying editorial, neurologist David Standaert of the University of Alabama's Heersink School of Medicine cautioned against drawing "overly optimistic" conclusions that lixisenatide may have completely prevented disease worsening. However, the difference between the two groups nonetheless "appears genuine and supports an effect of lixisenatide on the symptoms, and potentially the course, of Parkinson's disease," he said.Trial participants did encounter adverse effects of treatment. Researchers aimed to give the highest approved dose of lixisenatide for diabetes, but 36% of patients had side effects that were too severe at that level. Even with a lower dose, many still experienced adverse effects, with 46% reporting nausea and 13% reporting vomiting in the lixisenatide group, compared to 12% and 3%, respectively, in the placebo arm.Standaert suggested the main takeaway of the study is not so much the extent of the motor score change, but what it might signify. "The primary concern of most patients with Parkinson's disease is not their present condition — it is the fear of progression… If a three-point improvement in score on the MDS-UPDRS is the most that can be achieved with lixisenatide, then the value of treatment with the drug may be limited, especially in view of the adverse effects.""On the other hand, if the benefit of lixisenatide is cumulative, adding another three points each year over a period of 5 to 10 years or more, then this could be a truly transformative treatment," he said, adding "the next step is clearly trials of longer duration."

Phase 2Clinical Result

100 Deals associated with Insulin Glargine/Lixisenatide

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	A10AE54	-

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Diabetes Mellitus, Type 2	Switzerland	Sanofi-Aventis U.S. LLC	16 May 2002

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Diabetes Mellitus, Type 2	Discovery	Ukraine	Sanofi	01 Jan 2014
Diabetes Mellitus, Type 2	Discovery	Russia	Sanofi	01 Jan 2014
Diabetes Mellitus, Type 2	Discovery	Australia	Sanofi	01 Jan 2014
Diabetes Mellitus, Type 2	Discovery	Mexico	Sanofi	01 Jan 2014
Diabetes Mellitus, Type 2	Discovery	Chile	Sanofi	01 Jan 2014
Diabetes Mellitus, Type 1	Discovery	Japan	Sanofi	01 Sep 2012

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05413369 (SoliD, CTgov)	Phase 3	Diabetes Mellitus, Type 2	582	Insulin glargine/Lixisenatide+SGLT2 inhibitor+Metformin (iGlarLixi)	kfdlgphthu(mureryxmrv) = wpizdkqxow ededkkmdos (jqixnleult, rddlqhwgme - sxuhqbrhoh) View more	-	30 Oct 2024
				SGLT2 inhibitor+IDegAsp+Metformin (IDegAsp)	kfdlgphthu(mureryxmrv) = ubopyfcgkm ededkkmdos (jqixnleult, nuomhdljul - wfookobjsr) View more
NCT03798080 (LixiLan-L-CN, Pubmed \| Diabetes Obes Metab) Manual	Phase 3	Diabetes Mellitus, Type 2 \| Hyperglycemia	124	iGlarLixi	tefvadsghu(nockrctnhm) = cvofxzjuin gtzqacdprd (lygfmluzxh ) View more	Positive	03 Oct 2024
				iGlar	tefvadsghu(nockrctnhm) = jpcugonllw gtzqacdprd (lygfmluzxh ) View more
NCT05413369 (SoliD, ADA2024) Manual	Phase 3	Diabetes Mellitus, Type 2	582	iGlarLixi	(kbajxsrlee): Difference = -0.20 (95% CI, -0.33 to -0.07), P-Value = <0.001 View more	Non-inferior	21 Jun 2024
				IDegAsp
ADA2024	Not Applicable	-	-	iGlarLixi	cwkqicqukn(qekquekrph) = iepxdqdhxu tggtwthrri (kaeainbzxl, 4.3) View more	-	14 Jun 2024
				MDI	cwkqicqukn(qekquekrph) = witruoznwj tggtwthrri (kaeainbzxl, 3.7) View more
ADA2024	Not Applicable	Diabetes Mellitus, Type 2	-	iGlarLixi	uzsqbzlvic(syltoebaly) = qzpnmwxgwp kxwrgceycw (cjzpgfunii, 1.18 - 1.71)	-	14 Jun 2024
ADA2024	Not Applicable	-	-	iGlarLixi	rgehumngep(ddnwiyvbur) = iikalvgnji vdosypmdvd (qdbjaiwwqi, -3.4 to 0.75) View more	-	14 Jun 2024
				MDI	rgehumngep(ddnwiyvbur) = rqlgxehadq vdosypmdvd (qdbjaiwwqi, -1.2 to 3.3) View more
ADA2024	Not Applicable	Diabetes Mellitus, Type 2	-	iGlarLixi	(frkwycdidx) = oixhknezuq eknenciwqv (hzvemkrorw ) View more	-	14 Jun 2024
ADA2024	Not Applicable	Diabetes Mellitus, Type 2	-	iGlarLixi	okenzqdpnm(oipjiyrwjk) = chvwwemlhx yvgutnkzlf (rtgduqtqom ) View more	-	14 Jun 2024
				BID PI dosing	okenzqdpnm(oipjiyrwjk) = qpjealuwxt yvgutnkzlf (rtgduqtqom )
NCT05114590 (374-P \| 839-P \| Soli-CGM, CTgov)	Phase 4	Diabetes Mellitus, Type 2	124	Insulin glargine/Lixisenatide	ezqpnudabr(nicqrxtnmj) = quymhbsdzr lavwmhuywq (kxcpzngjyx, egrflaerhq - ldmeripkek) View more	-	24 May 2024
CHANCE (ADA2023)	Not Applicable	Diabetes Mellitus, Type 2	70	iGlarLixi	(qnuglfzcvu) = hjesdlwhps esoqngqmhz (ophaqsyhol ) View more	Positive	20 Jun 2023

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis